Molecular Subtype
Myeloproliferative Neoplasm, BCR-ABL1 Negative
CI-CAN-00003386Explore in graph →
Hematologic94 active trials2 approved drugs8 evidence items
- NCIt
- C198555
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00003386Explore in graph →
Clinical trials
333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (56)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07722611 | A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) | recruiting | Phase 2 / Phase 3 | 380 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07429266 | INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)(INTREPID) | recruiting | Phase 3 | 250 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | Sep 8, 2026 |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | active not recruiting | Phase 3 | 160 | PharmaEssentiaINDUSTRY | 9 | Aug 13, 2026 | clinicaltrials |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance(SURPASS ET) | active not recruiting | Phase 3 | 174 | PharmaEssentiaINDUSTRY | 8 | Jul 22, 2026 | clinicaltrials |
| NCT03480360 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | completed | Phase 3 | 21 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions(INDEPENDENCE) | active not recruiting | Phase 3 | 313 | CelgeneINDUSTRY | 26 | Jul 16, 2026 | clinicaltrials |
| NCT04576156 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | active not recruiting | Phase 3 | 327 | Geron CorporationINDUSTRY | 26 | Jul 8, 2026 | clinicaltrials |
| NCT04116502 | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera(MITHRIDATE) | recruiting | Phase 3 | 586 | University of BirminghamOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07539779 | Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis | not yet recruiting | Phase 2 / Phase 3 | 196 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis(SENTRY) | active not recruiting | Phase 3 | 353 | Karyopharm Therapeutics IncINDUSTRY | 20 | Apr 9, 2026 | clinicaltrials |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Apr 2, 2026 | clinicaltrials |
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT04472598 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis(TRANSFORM-1) | completed | Phase 3 | 252 | AbbVieINDUSTRY | 25 | Mar 23, 2026 | clinicaltrials |
| NCT05198960 | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms(AVAJAK) | recruiting | Phase 3 | 1,308 | University Hospital, BrestOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis(TRANSFORM-2) | active not recruiting | Phase 3 | 330 | AbbVieINDUSTRY | 30 | Jan 9, 2026 | clinicaltrials |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | terminated | Phase 3 | 252 | Incyte CorporationINDUSTRY | 17 | Oct 21, 2025 | clinicaltrials |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | terminated | Phase 3 | 177 | Incyte CorporationINDUSTRY | 19 | Oct 2, 2025 | clinicaltrials |
| NCT05481151 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | active not recruiting | Phase 3 | 111 | PharmaEssentiaINDUSTRY | 2 | Aug 13, 2025 | clinicaltrials |
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera(VERIFY) | active not recruiting | Phase 3 | 293 | Protagonist Therapeutics, Inc.INDUSTRY | 20 | Aug 7, 2025 | clinicaltrials |
| NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera(THRIVE) | active not recruiting | Phase 3 | 46 | Protagonist Therapeutics, Inc.INDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04655092 | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | recruiting | Phase 3 | 67 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06002490 | A Study to Evaluate P1101 in Japanese PV Patients | completed | Phase 3 | 21 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT00354120 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant(GLOBAL) | completed | Phase 2 / Phase 3 | 121 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT01387763 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms(DALIAH) | completed | Phase 3 | 202 | Thomas Stauffer LarsenOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia(PAC326) | terminated | Phase 3 | 311 | CTI BioPharmaINDUSTRY | 12 | Nov 18, 2021 | clinicaltrials |
| NCT02038036 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.(RESPONSE-2) | completed | Phase 3 | 149 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 20, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | terminated | Phase 3 | 327 | CTI BioPharmaINDUSTRY | 12 | Sep 29, 2020 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT01178281 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence(RESUME) | completed | Phase 3 | 267 | CelgeneINDUSTRY | 16 | Jul 17, 2019 | clinicaltrials |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | completed | Phase 3 | 222 | Incyte CorporationINDUSTRY | 18 | Mar 6, 2019 | clinicaltrials |
| NCT01632904 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | completed | Phase 3 | 110 | Incyte CorporationINDUSTRY | 7 | Nov 14, 2017 | clinicaltrials |
| NCT01949805 | Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera(PROUD-PV) | completed | Phase 3 | 257 | AOP Orphan Pharmaceuticals AGINDUSTRY | 14 | Nov 28, 2016 | clinicaltrials |
| NCT02523638 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients(PEN-PV) | completed | Phase 3 | 30 | AOP Orphan Pharmaceuticals AGINDUSTRY | 8 | Feb 17, 2016 | clinicaltrials |
| NCT02076815 | Anagrelide Retard in Essential Thrombocythemia(TEAM-ET) | completed | Phase 3 | 106 | AOP Orphan Pharmaceuticals AGINDUSTRY | 5 | Jul 29, 2015 | clinicaltrials |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | terminated | Phase 3 | 365 | Consorzio Mario Negri SudOTHER | 1 | Jul 20, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials